TCR T Cells + Azacitidine for Acute Myeloid Leukemia

This trial explores a new combination treatment for individuals with acute myeloid leukemia (AML) who still have minimal residual disease (MRD) after chemotherapy. It uses a special type of T cells, called FH-WT1-E50 TCR T Cells, taken from the patient's own blood and modified to target a specific protein on cancer cells. This is combined with azacitidine, a drug that slows cancer growth. The trial aims to determine the best dose and assess the safety and side effects of this treatment. It may suit someone with AML (excluding the M3 subtype) who has undergone chemotherapy and still has minor traces of the disease. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial protocol does not specify if you must stop taking your current medications. However, you need to be at least two weeks or five half-lives from your last systemic treatment before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that FH-WT1-E50 TCR T cells are safe. These specialized cells target cancer cells while sparing normal tissues. Patients who received these cells did not experience cancer recurrence and had no major side effects.

Azacitidine, a treatment for acute myeloid leukemia (AML), is generally well-tolerated, though some patients may need dose adjustments due to side effects like low blood counts or fatigue. Overall, azacitidine extends survival and maintains quality of life for AML patients.

Unlike the standard treatments for acute myeloid leukemia, such as chemotherapy and stem cell transplants, the FH-WT1-E50 TCR T cells offer a unique approach by using the body's own immune system to fight cancer. This treatment involves genetically modifying T cells to specifically target and destroy leukemia cells, which is a new mechanism of action compared to traditional methods. Researchers are excited about this treatment because it has the potential to be more precise and less harmful than current options, potentially reducing side effects and improving outcomes for patients.

This trial will investigate the combination of FH-WT1-E50 TCR T cells and azacitidine for treating acute myeloid leukemia (AML). Studies have shown that WT1-specific TCR-T cells can help prevent AML recurrence. In one study, patients who received these cells did not experience a relapse for over 44 months. These cells can target and attack cancer cells without harming healthy tissues. Additionally, WT1-specific T cells are generally well tolerated and typically do not cause serious side effects. Research suggests these specially designed T cells could play a crucial role in fighting AML.⁶⁷⁸⁹¹⁰